Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...
Third article in Paolo's Biotech Notes series. PDF attached and uploaded. Additionally, Paolo has provided a relevant timely article. ContraFect Corp (CFRX) has a promising pipeline with a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results